1
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
--------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15 (d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event
reported): June 29, 2000
United Therapeutics Corporation
--------------------------------------------------
(Exact Name of Registrant as Specified in Charter)
Delaware 000-26301 52-1984749
(State or Other (Commission (I.R.S. Employer
Jurisdiction of File Number) Identification
Incorporation) Number)
1110 Spring Street
Silver Spring, MD 20910
- ----------------------------------- --------
(Address of Principal Executive (Zip
Offices) Code)
Registrant's telephone number, including area code:
(301) 608-9292
---------------------
2
ITEM 5. OTHER EVENTS.
On June 29, 2000, the Registrant issued a press release, a copy of
which is attached hereto and incorporated herein by this reference.
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS
(a) Not applicable.
(b) Not applicable.
(c) Exhibits
Exhibit No. Description
----------- -----------
99.1 Registrant's press release dated June 29, 2000
3
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
United Therapeutics Corporation
(Registrant)
Date: June 29, 2000 By: /s/ Martine A. Rothblatt
----------------------------------
Name: Martine A. Rothblatt
Title:Chairman and CEO
4
EXHIBIT INDEX
Exhibit No. Description
- ----------- -----------
99.1 Registrant's press release dated June 29, 2000